journal of hepatology

hepatology research : the official journal of the japan society of hepatology

[1] Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

[2] Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

[3] treatment of chronic hepatitis c among injecting drug users: a 5-year follow-up

[4] evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis c

[5] efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

[6] very-low-dose pegylated interferon α2a plus ribavirin therapy for advanced liver cirrhosis type c: a possible therapeutic alternative without splenic intervention

[7] potential of g-csf supplementation to counter the neutrophil effects of standard peg-ifnα plus ribavirin combination therapy for treating hcv-related cirrhosis

[8] Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

[9] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[10] Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

[11] Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

[12] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[13] Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

[14] Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies

[15] Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

[16] Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

[17] Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

[18] Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

[19] Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia

[20] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[21] Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

[22] Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy

[23] Ribavirin aerosol for acute bronchiolitis

[24] Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

[25] Ribavirin aerosol for acute bronchiolitis.

[26] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

[27] Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial

[28] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

[29] Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

[30] Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

[31] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[32] Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

[33] Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

[34] A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

[35] Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease

[36] Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat

[37] Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection

[38] Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database

[39] Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group

[40] Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants

[41] Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

[42] Early ribavirin treatment of respiratory syncytial viral infection in high-risk children

[43] Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

[44] Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease

[45] Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

[46] on-treatment elevation in hepatic transaminases during hcv treatment with ombitasvir, paritaprevir, dasabuvir, ritonavir, and ribavirin: a case series

[47] arenaviruses and lethal mutagenesis. prospects for new ribavirin-based interventions

[48] comparative efficacy of combined treatment with intron a and pegintron in combination with ribavirin in patients with chronic hepatitis С

[49] pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis c after liver transplantation: from a canadian experience to recommendations for therapy

[50] the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

[51] increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy

[52] boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis c virus genotype 1 in hiv–hcv co-infected patients: final results of the spanish boc hiv–hcv study

[53] efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

[54] retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

[55] efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis c

[56] response to pegylated interferon plus ribavirin in patients with hepatitis c virus genotype 6a infection from guangdong and guangxi province of china

[57] effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis c infection

[58] very-low-dose pegylated interferon α2a plus ribavirin therapy for advanced liver cirrhosis type c: a possible therapeutic alternative without splenic intervention

[59] potential of g-csf supplementation to counter the neutrophil effects of standard peg-ifnα plus ribavirin combination therapy for treating hcv-related cirrhosis

[60] Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

[61] Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

[62] In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin

[63] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

[64] Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

[65] Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

[66] The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis

[67] A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin